A proprietary crystalline salt form of nicotinamide riboside — NR fumarate, branded Restorin NR — achieved blood NAD+ elevations in aged mice equivalent to NMN or NR chloride at roughly one-third the molar dose (0.33 vs. 1 mmol/kg/day, n=11 per group). At matched doses of 1 mmol/kg/day, Restorin NR produced significantly higher circulating NAD+ than either comparator. The mechanism proposed is improved stability in the circulatory system relative to standard NR chloride salt formulations.
The finding lands in a crowded but still-unsettled space. NMN vs. NR comparisons in humans have yielded inconsistent superiority claims, partly because tissue uptake — not just blood levels — determines functional benefit. This study measures only circulating NAD+, leaving open the critical question of whether intracellular or tissue NAD+ replenishment (particularly in muscle, liver, and brain) is proportionally enhanced. The aged murine model is relevant but not directly translatable; rodent NAD+ metabolism differs meaningfully from humans in baseline decline rates and tissue distribution. Crucially, the study originates from Seragon Biosciences, the commercial developer of Restorin NR — a significant conflict of interest requiring independent replication. The dose-efficiency advantage, if confirmed in humans, would be commercially and clinically meaningful: lower effective doses reduce cost and potential off-target effects from high-dose niacinamide metabolites. Incremental rather than paradigm-shifting, but worth monitoring for independent human pharmacokinetic trials.
